Henry Schein stock holds steady as Q2 FY26 earnings top estimates
Published on 08/26/2026 at 08:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Henry Schein stock, issued by Henry Schein Inc. (US42548G1040), traded at $89.65 at the close of August 25, 2026, on the Nasdaq, slightly above the previous close of $89.51 and leaving the shares up 30.7% over the past 12 months as investors digest the company’s latest earnings and guidance.
Earnings beat in Q2 FY26
According to market data as of August 25, 2026, Henry Schein reported Q2 fiscal 2026 earnings per share of $1.27, ahead of an earlier estimate of $1.24 for the period. In the same quarter, the company generated revenue of $3.46 billion and net income of $94 million, implying a profit margin of 2.72% for Q2 fiscal 2026 based on the available figures. These numbers show that while profitability remains modest in percentage terms, the company is still expanding its top line and maintaining positive earnings in the current fiscal year.
The Q2 fiscal 2026 results also provide a reference point for how Henry Schein is balancing growth and margin discipline. With revenue at $3.46 billion and net income at $94 million in the quarter, the implied profit margin of 2.72% underscores that the business operates on relatively thin margins but is able to deliver consistent profitability. For many investors, a low single-digit margin means that small improvements in cost efficiency or pricing can translate into notably higher earnings leverage over time when volumes continue to grow.
Guidance and analyst expectations
A recent earnings-related overview indicates that Henry Schein has set its full-year 2026 earnings per share guidance in a range from $5.29 to $5.39, framing the company’s internal expectations for the current fiscal year. Within that context, one research update cited a reduction of a Q3 2026 EPS estimate from $1.38 to $1.33, while still projecting full-year 2026 EPS of $5.32, which remains inside the company’s guidance range and marginally below the midpoint of $5.34. The same overview noted that the consensus estimate for Henry Schein’s current full-year earnings stands at $5.35 per share and described the consensus rating as a moderate buy, with a consensus target price of $92.93 per share as of late August 2026.
These comparisons help quantify how the company’s own targets align with external expectations. With guidance of $5.29 to $5.39 and a projected EPS of $5.32 by one estimate, the forecast is slightly below the midpoint but still within the official range, suggesting that analysts see only limited downside relative to management’s outlook. At the same time, a consensus EPS of $5.35 is modestly above that individual projection and also close to the midpoint of guidance, pointing to a generally constructive but not euphoric view of Henry Schein’s earnings trajectory for fiscal 2026.
Stock performance and valuation context
Market data as of August 25, 2026, show that Henry Schein stock closed at $89.65 on the Nasdaq, representing a gain of 0.16% on the day compared with the prior close of $89.51. Over the past year, the shares have advanced 30.7%, meaning the stock has outperformed the broader market over that period and delivered solid price appreciation for long-term holders. The trading profile on that day also shows a previous close of $89.51 and an intraday open of $89.19, indicating that the stock remained within a relatively tight range during the latest session while still sitting just below the consensus price target of $92.93.
The relationship between the current price level and the consensus target offers an additional quantitative gauge for investors. With Henry Schein trading at $89.65 and a consensus target of $92.93, the implied upside based on that benchmark is $3.28 per share, or roughly 3.7% above the latest close when expressed in percentage terms. While such a gap is not large, it suggests that the market price already reflects much of the expected earnings growth that analysts foresee for fiscal 2026, leaving a modest cushion between the current valuation and the average target level for the stock.
Dental and medical supply portfolio
Henry Schein’s core business centers on distributing dental and medical products to office-based practitioners, and its product portfolio spans consumables, equipment, and related services. A representative segment is the company’s dental supplies and equipment offering, which provides dental practices with everyday materials for procedures, infection prevention products, and larger items such as chairs, imaging systems, and digital workflow tools. The breadth of this portfolio allows Henry Schein to bundle solutions and support customers across a wide range of clinical needs.
Beyond traditional supplies, Henry Schein also offers technology and value-added services connected to practice management and patient engagement. These services can include software solutions that help dental and medical offices manage scheduling, billing, and records, as well as integration of digital imaging or clinical workflow systems. By combining physical products with digital tools and support, the company seeks to deepen customer relationships and create more durable revenue streams that are less sensitive to short-term fluctuations in individual product categories.
Current trading snapshot
As of the close on August 25, 2026, Henry Schein stock traded on the Nasdaq at $89.65 in U.S. dollars, reflecting a small daily gain and positioning the shares slightly below the consensus analyst price target. The recent share performance, including a 30.7% increase over the past year, underscores that the market has rewarded the company for delivering Q2 fiscal 2026 earnings per share of $1.27, which exceeded prior estimates, and for maintaining a full-year 2026 EPS guidance range of $5.29 to $5.39.
Fact box
Company: Henry Schein Inc.
ISIN: US42548G1040
Ticker: HSIC
Exchange: Nasdaq
Price (as of August 25, 2026, 4:00 p.m. ET): $89.65 USD
Sector / Industry: Health care / Health care distributors
